OR WAIT null SECS
European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.
Revolutionary therapies restructure pharmaceutical manufacturing.
There are positive indications for future growth.
March 18, 2024
Cellares CEO Fabian Gerlinghaus discusses the nuts and bolts of counterflow centrifugal elutriation and electroporation innovations and optimization, while hinting at big news on future release testing of products, as a product itself.
March 16, 2024
Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection
March 14, 2024
In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.
Webinar Date/Time: Wed, Apr 24, 2024 11:00 AM EDT
March 12, 2024
In an interview, Fabian Gerlinghaus of Cellares outlines a paradigm change in both hardware and software, regulatory expansions, and some positive cost outcomes for the CGT field.
The Cell Shuttle platform will manufacture cell therapies for its first clinical trials by the end of the year.
The European company has seen its business increase by 47% in North America.
March 11, 2024
The Alliance will receive the NSF Regional Innovation Engines Development Award and $1 million in funding.
March 08, 2024
The facility producer’s new innovation hub will offer manufacturing, life sciences, and infrastructure services.
March 07, 2024
Cellares CEO Fabian Gerlinghaus shares how an automated, closed-production platform with a small footprint can dramatically impact cost savings and scalability for cell and gene therapies.